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In order to determine the antiarrhythmic efficacy and 
safety of oral flecainide acetate (FA) in man, a placebo 
controlled dose-ranging and short-term oral maintenance 
study was undertaken in 13 patients (pts) with chronic, 
ventricular ectopy (VE) of frequency >600 VEll2 hrs. 
During a 2 day placebo control period, 11113 maintained 
stable VE frequency (mean 11,254/12 hr,range 653-35.551) 
and entered dose-ranging. Dosage was increased in in- 
crements at 3 day intervals from 100-300 mg/12 hr until 
95% VE suppression, limiting side effects, or dosage max- 
imum was attained. Ten pts completed dose-ranging, and 
pt 11 experienced a transient ischemic attack and was ex- 
eluded. Of the 10 pts, 9(90%) were complete responders 
(CR) (mean suppression 98.7%. range 96.1-100%). and one 
responded partially (68% suppression). Repetitive VE was 
totally eliminated in all 10 pts. Pt 11 showed 77% VE sup- 
pression on 100 mg/12 hr before exclusion. Of CR, 2 pts 
ended dose-ranging successfully at 100 mg, 5 at 200 mg, 
and 2 at 250mg/12 hr. Average dose calculated to achieve 
95% suppression was 169 mgll2 hrs. A 3 day placebo- 
controlled drug washout period was accompanied by a 
significant return in VE in each of the 9 CR. VE first re- 
curred at 21.9 hrs (range 7-40), and by 3 days VE aver- 
aged149.6% of control frequency. During the subsequent 
outpt trial, FA remained highly effective with total and 
average VE suppression of 98.0% and 94.6%. respectively. 
ECG response included prolongation (pCO.01) of PR(16.5%) 
and QRS (10.6%). Echocardiographic Cl was unchanged. 
FA was well tolerated except for headache in 2 pts. Thus 
FA appears to be a highly effective antiarrhythmic in man. 
SUCCESSFUL CONTROL OF THE CHRONIC FORM OF SUPRAVENTRI- 
CULAR TACHYCARDIA WITH ORAL VERAPAMIL HYDROCHLORIDE 
Ruey J. Sung. MD, FACC; Candy Raphan, RN; Zulfikar Juma, 
MD, Arrhythmia Control Clinic, Department of Medicine, 
University of Miami, Miami, Florida. 
Chronic supraventricular tachycardia (SVT), in contrast 
to the paroxysmal form of SVT, is characterized by its 
almost incessancy interposed by short periods of sinus 
rhythm. Verapamil hydrochloride (V) was used to treat 
12 patientscpts) with the chronic form of SVT at rates 
ranging from 140 to 180 beats per minute. Three pts 
had sinus nodal reentrant tachycardia, 4 pts atrio- 
ventricular (A-V) nodal reentrant tachycardia and 5 pts 
A-V reciprocating tachycardia involving concealed retro- 
grade conducting bypass tracts. All 12 pts were sympto- 
matic and were resistant or intolerant to digitalis, pro- 
pranolol, quinidine, procainamide and disopyramide used 
alone or in various combinations. V was given orally at 
dosages ranging from 320 to 800 mg per day and all pts 
were followed at bimonthly intervals at our arrhythmia 
control clinic. With a follow-up period of 5-23 (mean 
14.6) months, all 12 pts had symptomatic improvement. 
Repeated holter monitoring during V therapy demonstrated 
that E/12 pts manifested only atria1 echo phenomenon and 
4/12 pts slow, short-lived SVT at rates of less than 100 
beats per minute. The therapeutic plasma V concentrations 
measured 112 to 572.6 (mean 232 f 127) ng/ml. One pt 
developed headache, 1 pt constipation and 2 pts peri- 
pheral edema presumably due to venous relaxation effect 
of V. Each of these side effects was mild and clinically 
manageable. We conclude that oral V therapy is safe and 
effective for pts with the chronic form of SVT. In ad- 
dition, this study suggests that V therapy may be tried 
before contemplating pacemaker therapy or surgical inter- 
vention in these pts. 
ROLE OF SERUM T4 AND REVERSED T3 IN MONITORING ANTIAR- 
RHYTHMIC EFFICACY AND TOXICITY OF AMIODARONE IN RESISTANT 
ARRHYTHMIAS 
Koonlawee Nademanee, MD; S. Melmed, MD; JoAnn Hendrickson, 
BS; A.W. Reed, MS; Jerome H. Hershman, MD; Bramah N. Singh 
MD, FACC, Wadsworth VA Hospital, Los Angeles, California 
Amiodarone (Am), a potent iodinated antiarrhythmic drug 
increases serum T4 and reversed T3 (rT3) without producing 
clinical hyper or hypo-thyroidism, Thus, T4 and rT3 and 
QTc were measured serially in 15 euthyroid pts with resis- 
tant (to other agents) cardiac arrhythmias (7 ventricular, 
8 atrial) before, during and after withdrawal of Am (600- 
1000 mg/day) therapy and correlated with drug toxicity and 
antiarrhythmic efficacy (AE). documented by serial 24 hr 
Ho1 ter analysis. Results (mean+S.D.; *p<O.OOl): 
Predrug 
3 week 
Peak (2-5 wk) 
T4 vg/dl 
7.ak2.2 q#@- 04@03 
12.1k2.8 67+22 0:48+0:02 
15.9+3.2* 84?21* 0.49+0.04* 
6 wk dfter 
drug stopped 9.521.9 55+5.5 0.46t0.04 
Amiodarone increased T4 and rT3 in all patients; a linear 
correlation was found between an increase in rT3, AE and 
Q-Tc. AE was invariably associated with rT3 level >55 ng/ 
dl and drug side effects with ~100 ng/dl. The correlation 
with T4 was less striking. On drug withdrawal, side ef- 
fects disappeared when rT3 fell ~100 ng/dl and arrhythmias 
returned at levels’ ~55 ng/dl . 
Conclusions: 1) Serum rT3 provides a sensitive index to 
monitor efficacy (55-100 ng/dl) and toxicity (~100 ng/dl) 
of Amiodarone and 2) the data provides evidence for the 
drug producing a selective inhibition of T3 action on the 
heart as a potential basis for its antiarrhythmic effect. 
FLECAINIDE ACETATE, A NEW ANTIARRHYTHMIC AGENT: 
DOSE-RANGING AND EFFlCACY STUDY 
Morrison Hodges, MD, FACC; J. Mark Haugland, MD; Gregory 
Granrud, MD; Richard W. Asinger, MD; Frank L. Mikell, MD; 
Jeananne Krejci, RN. Hennepin County Medical Center and the 
University of Minnesota, Minneapolis, MN. 
Flecainide acetate (R-818) is a new antiarrhythmic agent 
with Class I properties. Potential advantages include a long 
plasma half-life cave: 14 hr); effectiveness by both oral and IV 
routes; efficacy at relatively small doses; and few serious side 
effects noted to date. We evaluated flecainide with a single-blind 
dose-ranging and efficacy study in 9 patients with frequent 
ventricular ectopic depolarizations (VEDr.1. Patients were hos- 
pitalized and the ECG was monitored continuously by tape record- 
ings which were analyzed quantitatively in a blinded fashion. Two 
days of placebo BID were followed by three increasing oral doses 
of flecainide (100, 200 and 300 mgm BID for 3 days each) until 
complete suppression or the 300 mgm BID dose was reached; 3 
days of placebo BID were then observed to assure return of 
baseline rhythm and to evaluate plasma pharmacokinetics. During 
the a-day control period, the patients averaged 15.2 VEDs/min 
(range 1.3-50.01, and all patients were observed to have complex 
ventricular arrhythmias (> lown Class II). At the most effective 
dose (200 mgm BID in 6 pts, 300 mgm BID in 3 pts), average VED 
suppression was 96.0% (range 7’7.9%-lOO%), with 6 of the 9 
achieving 100% suppression. During placebo washout, VED return 
averaged 146% of control. Outpatient treatment resulted in 
average suppressions of 99.6% and 99.5% at 1 and 2 wks, 
respectively. There were no significant changes in blood pressure 
or heart rate, but the PR, QRS and QTc intervals increased by 
29%, 24% and 7% respectively fp < .05 for all). Observed side 
effects were an occasional sense of unsteadiness (4 pts), transient 
blurring of vision (1 pt), and a sense of warmth (1 pt). No side 
effect was serious enough to require discontinuation of drug. We 
conclude that oral flecainide, 200 or 300 mgm BID, is highly 
effective at suppressing VEDs and complex ventricular arrhyth- 
mias. Side effects in these 9 pts were minimal. 
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